[Endothelin antagonists and their role in pharmacotherapy].
Endotelina (ET-1) is the polypeptide about wide spectrum of physiological effects, involved in pathophysiology of cardiovascular and neoplastic diseases. Thus, ET-1 blocking becomes modern therapeutic target. The endothelin receptor antagonists (ERA)--sentans are the intensely studied agents, already approved for an alternative pulmonary hypertension therapy and hormone-resistant prostate cancer treatment. The promising results of conducted clinical trials suggest the possible extension of ERA application in other clinical entities in the close future. The article shortly describes present studied endothelin receptor antagonists and rationale for their introduction to the general clinical practice.
Dobrek
Łukasz
Ł
Uniwersytet Jagielloński, Collegium Medicum, Katedra Patofizjologii. lukaszd@mp.pl
Thor
Piotr
P
D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000037:antagonists & inhibitors*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy
D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1